Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades

Journal of Virology

Volumn 76, Issue 18, 2002, Pages 9035-9045

  Gorny, Miroslaw K ^a   Williams, Constance ^a   Volsky, Barbara ^a   Revesz, Kathy ^a   Cohen, Sandra ^a   Polonis, Victoria R ^a   Honnen, William J ^a   Kayman, Samuel C ^a   Krachmarov, Chavdar ^a   Pinter, Abraham ^a   Zolla Pazner, Susan ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY V3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LINEAR REGRESSION ANALYSIS; MONONUCLEAR CELL; MURINE LEUKEMIA VIRUS; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CELL LINE, TRANSFORMED; CROSS REACTIONS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; HYBRIDOMAS; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; VIRION;

EID: 0036720793     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.18.9035-9045.2002     Document Type: Article

References (67)

1. Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape
2. Neutralization of primary and T-cell line adapted isolates of the human immunodeficiency virus type 1: Role of V3 specific antibodies
3. Carbohydrate determinant NeuAc-GalB(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120
4. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
5. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
6. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by super-infection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
7. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate
8. Biological features of HIV-1 that correlate with virulence in the host
9. Neutralization of primary HIV-1 virus isolates by the broadly reactive anti-V3 monoclonal antibody 447-52D
10. Human immunodeficiency virus (HIV) antigens: Structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins
11. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: Relationship to neutralization
12. Crystal structure of the principal neutralization site of HIV-1
13. Structure-based design of a constrained-peptide mimic of the HIV-1 V3 loop neutralization site
14. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
15. Production of human monoclonal antibodies via fusion of Epstein-Barr virus-transformed lymphocytes with heteromyeloma
16. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades
17. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and inter-clade cross-reactivity
18. Effects of oligomerization on the epitopes of the Human Immunodeficiency Virus Type 1 envelope glycoproteins
19. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein
20. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
21. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees
22. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
23. Neutralization of HIV-1 primary isolates by poly-clonal and monoclonal human antibodies
24. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies
25. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
26. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity
27. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
28. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
29. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1
30. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
31. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: Further clarifications
32. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type I isolate envelope
33. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells
34. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay
35. Characterization of HIV-1 neutralization escape mutants
36. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
37. HIV-1 neutralization: Evidence for rapid, binding/postbinding neutralization from infected humans, chimpanzees, and gp120 vaccinated animals
38. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 (IIIB) infection of chimpanzees
39. Mapping of epitopes exposed on intact HIV-1 virions: A new strategy for studying the immunologic relatedness of HIV-1
40. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M
41. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes
42. Type-specific neutralization of the human immunodeficiency virus with antibodies to envencoded synthetic peptides
43. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex
44. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen
45. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
46. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
47. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120
48. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer
49. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain
50. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization
51. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
52. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs
53. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Poliovirus vaccination
54. Construction and testing of mouse-human heteromyelomas for human monoclonal anti-body production
55. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
56. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4 immunoglobulin G
57. IIIB V3 peptide
58. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
59. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
60. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results
61. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype
62. Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation
63. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
64. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
65. HIV-1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon
66. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV
67. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain